Page 8 - Co Diagnostics News Today

/PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of...

Dublin, April 18, 2022 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country,...

/PRNewswire/ -- The "Molecular Diagnostics at the Point of Care: By Application, Technology, Place, Product and by Country, with COVID-19 PoC Breakout and...

Co-Diagnostics (NASDAQ:CODX – Get Rating) updated its first quarter 2022 earnings guidance on Thursday. The company provided earnings per share guidance of $0.170-$0.200 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.110. The company issued revenue guidance of $21 million-$22 million, compared to the consensus revenue estimate of $21.28 […]

Zacks Investment Research upgraded shares of Co-Diagnostics (NASDAQ:CODX – Get Rating) from a hold rating to a buy rating in a report published on Tuesday, Zacks.com reports. They currently have $7.00 price target on the stock. According to Zacks, “Co-Diagnostics Inc. is a molecular diagnostics company. It develops, manufactures and markets a new, state-of-the-art diagnostics […]

/PRNewswire/ -- The "COVID-19 Diagnostics: Global C19 Diagnostic Market Forecast by Technology, Product, Channel and Country - Assay Volumes and Market Size...

HC Wainwright restated their buy rating on shares of Co-Diagnostics (NASDAQ:CODX – Get Rating) in a report published on Friday morning, TipRanks reports. The firm currently has a $15.00 target price on the stock. A number of other research firms have also recently commented on CODX. Sidoti began coverage on shares of Co-Diagnostics in a […]

Co-Diagnostics (NASDAQ:CODX – Get Rating) issued its quarterly earnings results on Thursday. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of $0.12 by $0.13, Fidelity Earnings reports. Co-Diagnostics had a return on equity of 50.81% and a net margin of 40.11%. During the same quarter last year, the firm […]

Dublin, March 24, 2022 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19...

/PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular...